Last Updated : May 25, 2023
Details
FilesGeneric Name:
eltrombopag
Project Status:
Active
Therapeutic Area:
Severe Aplastic Anemia (SAA)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0777-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
For the treatment of
adult patients with severe aplastic anemia (SAA).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | April 17, 2023 |
---|---|
Call for patient/clinician input closed | June 12, 2023 |
Review initiated | May 24, 2023 |
Clarification: - Committee meeting date to be determined. | |
Expert committee meeting (initial) |
Files
Last Updated : May 25, 2023